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Abstract  20 
Dietary zinc recommendations vary widely across Europe due to the heterogeneity of 21 
approaches used by expert panels. Under the EURRECA consortium a protocol was designed 22 
to systematically review and undertake meta-analyses of research data to create a database 23 
that includes “best practice” guidelines which can be used as a resource by future panels 24 
when setting micronutrient recommendations.  As part of this process, the objective of the 25 
present study was to undertake a systematic review and meta-analysis of previously published 26 
data describing the relationship between zinc intake and status in adults.   Searches were 27 
performed of literature published up to February 2010 using MEDLINE, Embase, and 28 
Cochrane Library.  Data extracted included population characteristics, dose of zinc, duration 29 
of study, dietary intake of zinc, and mean concentration of zinc in plasma or serum at the end 30 
of the intervention period. An intake-status regression coefficient ( ) was estimated for each 31 
individual study, and pooled meta-analysis undertaken. The overall pooled  for zinc 32 
supplementation on serum/plasma zinc concentrations from RCTs and observational studies 33 
was 0.08 (95% CI 0.05, 0.11; p<0.0001; I2 84.5%). An overall  of 0.08 means that for every 34 
doubling in zinc intake, the difference in zinc serum or plasma concentration is  (20.08 = 35 
1.06), which is 6%. Whether the dose-response relationship, as provided in this paper, could 36 
be used as either qualitative or quantitative evidence to substantiate the daily zinc intake dose 37 
necessary to achieve normal or optimal levels of biomarkers for zinc status, remains a matter 38 
of discussion. 39 
 40 
 41 
 42 
 43 
 44 
 45 
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 46 
Introduction 47 
Dietary zinc recommendations vary widely across Europe due to the heterogeneity of 48 
approaches used by expert panels (1). There is a need for a harmonised approach that is 49 
transparent and based on the best quality data and methods available.  Traditionally, the 50 
factorial approach is used in the determination of zinc requirements.  This method seeks to 51 
estimate the zinc intake required to meet physiological requirements for growth, metabolism 52 
and tissue repair while replacing obligatory losses.  An alternative approach is to examine the 53 
dose-response relationship between intake and biomarkers of status and also between intake 54 
and health outcomes.  This information could then be integrated using a mathematical model 55 
to provide an insight into the level of zinc intake required for optimal health based on a range 56 
of parameters and indices of health that are known to be dependent upon dietary zinc intake 57 
(2). To this end, the members of the European Micronutrient Recommendations Aligned 58 
(EURRECA)  Network of Excellence have undertaken a series of systematic reviews of zinc-59 
intake-status relationships, according to rigorous protocols defined by consortium members 60 
and external experts (2) .  This paper presents the results of the systematic review and meta-61 
analysis of the dose response relationship between dietary zinc intake and zinc status using 62 
novel methodology developed by members the EURRECA consortium.   63 
The assessment of zinc status is notoriously problematic for zinc, as a sensitive, 64 
specific biomarker for zinc has not yet been identified (3).  A systematic review and meta-65 
analysis of biomarkers of zinc status  was undertaken in 2009 (4).  For many putative 66 
biomarkers (such as the zinc concentrations found in the cellular components of whole blood) 67 
there were insufficient data to arrive at a definitive conclusion regarding their efficacy as a 68 
biomarker of zinc status, however plasma (or serum) zinc concentration was responsive to 69 
both zinc supplementation and zinc depletion and is the most widely reported biomarker for 70 
zinc. Hair and urine zinc concentrations were also considered to be potentially useful 71 
biomarkers in response to zinc supplementation. 72 
The purpose of this study was to systematically and quantitatively assess the dose 73 
response relationships relevant to deriving zinc recommendations based on intervention 74 
studies, cohort (nested case control) studies and cross-sectional studies. The specific 75 
questions to be addressed were; what is the effect of intake on indicators of exposure or body 76 
stores (i.e. biomarkers)? What factors affect this relationship?  77 
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The data used in this meta-analysis were extracted from published studies (RCTs, 78 
prospective cohort studies, nested case-control studies and cross-sectional), performed in 79 
healthy adult and elderly populations, reporting the relationship between zinc status (plasma 80 
or serum zinc, hair or urine zinc concentration) and intake from supplements, fortified diets 81 
or natural food diets.  82 
 83 
Methods 84 
Search strategy  85 
This research was conducted within the framework of the European Micronutrient 86 
Recommendations Aligned (EURRECA) Network of Excellence that aims to identify the 87 
micronutrient requirements for optimal health in European populations (www.eurreca.org). 88 
This research was part of a wider review process to identify studies assessing the effect of 89 
zinc intake on different outcomes (biomarkers of zinc status and health outcomes). The wider 90 
searches were performed of literature published up to and including February 2010 using  91 
Ovid MEDLINE, Embase (Ovid), and the Cochrane Library (CENTRAL) using search terms 92 
for (‘study designs in humans’) AND (zinc) AND (intake OR status). Both indexing and text 93 
terms were used and languages included were restricted to those spoken in the EURRECA 94 
Network (English, Dutch, French, German, Hungarian, Italian, Norwegian, Polish, Spanish, 95 
Greek, and Serbian.). The full Ovid MEDLINE search strategy can be found in Table 1. 96 
Reference lists of retrieved articles and published literature reviews were also checked for 97 
relevant studies. Authors were contacted to request missing data or clarify methods or results. 98 
The search process is illustrated in Figure 1. 99 
 100 
Criteria for the consideration of studies for this review 101 
Included studies were RCTs, prospective cohort studies, nested case-control studies and 102 
cross-sectional studies in healthy human populations that supplied zinc supplementation 103 
(RCTs) or measured dietary zinc intake with either a validated food frequency questionnaire, 104 
a dietary history method, a 24-hour recall method for at least 3 days, or a food record/diary 105 
for at least 3 days (observational studies). Studies had to be conducted in apparently healthy 106 
adult and elderly (human) populations aged ≥18 years and supplied zinc supplementation 107 
either as capsules or part of a fortified meal. If supplemental zinc was provided as a 108 
component of a fortified meal, studies were only considered acceptable if zinc was the only 109 
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constituent that was different between treatment groups. Biomarkers of zinc status included 110 
plasma/serum, urine and hair zinc concentrations. Only studies that reported sufficient data or 111 
had sufficient data obtainable from the authors to estimate and SE( ) for the assumed linear 112 
relation on the loge-loge scale were included. Studies were excluded if they were a group 113 
RCT (community trial), or were commentaries, reviews, or duplicate publications from the 114 
same study. Studies were excluded if adults were hospitalised, had a chronic disease or if 115 
supplemental zinc was provided for less than 2 weeks. 116 
 117 
Selection of articles 118 
Of 4719 identified articles in the wider search on zinc intake, status and priority health 119 
outcomes in all populations, 2557 were excluded based upon screening of the title and 120 
abstract. Two independent reviewers screened 10% of the abstracts in duplicate and any 121 
discrepancies were discussed before screening the remaining references. Following 122 
subdivision into appropriate population groups the full texts of the 1231 manuscripts were 123 
assessed to determine inclusion and exclusion by two independent reviewers and 124 
disagreements rectified through discussion. 1147 studies were excluded because they did not 125 
meet the inclusion criteria. Of the remaining 84 studies, 54 studies were excluded as they 126 
related either zinc intake or status directly to a health endpoint, but they had not investigated 127 
the relationship between zinc intake and zinc related to biomarkers. A further 17 studies were 128 
excluded from the meta-analysis because study participants were not healthy, insufficient data 129 
was reported, data was duplicated, or the dosage and duration was unclear. For the purpose of 130 
this meta-analysis, 10 RCTs and 3 observational studies remained. The characteristics of the 131 
included studies are presented in Table 2 and Table 3 respectively.   132 
 133 
Data extraction 134 
For each of the identified manuscripts, data was extracted independently by two reviewers 135 
into a standardized database. Extracted data included population characteristics, dose of zinc 136 
in intervention and placebo supplements, duration of the study, dietary intake of zinc, and 137 
mean concentration of zinc in plasma or serum at the end of the intervention period.  138 
Serum/plasma zinc concentrations were converted to µmol/L when applicable. 139 
 140 
Data synthesis  141 
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Two RCTs that reported data for two zinc-treated groups and two control groups were treated 142 
as two independent estimates in the analysis (5; 6). Where RCTs provided outcome data for 143 
two or more zinc-treated group, they were included as separate estimates in the meta-analysis 144 
(7; 8; 9; 10; 11). Where zinc status was measured at different time points within the same 145 
population only the final measure was used in the analysis (12; 13).  One observational study 146 
reported data from males and females and these were treated as two estimates in the meta-147 
anaysis (14).  If dietary intake of zinc (in addition to the intervention) was not reported in the 148 
RCTs, a value of 9.7 mg/day was imputed, which was the mean dietary intake level of the 149 
RCTs that did report dietary zinc intake. As mean baseline serum/plasma zinc concentrations 150 
were infrequently reported in the RCTs, the serum/plasma zinc concentrations in the control 151 
group were used as a proxy of the baseline serum/plasma zinc concentrations for our 152 
analyses.  153 
 154 
Statistical analyses 155 
A stratified random effects meta-analysis was conducted using STATA version 11 (College 156 
Station, TX), with one subgroup combining the evidence from RCTs and the other subgroup 157 
combining the evidence from observational studies. As serum/plasma zinc levels have been 158 
reported to decline with age (15), a separate stratified random effects meta-analysis compared 159 
zinc intake and status according to age in RCTs (< 55 years and  ≥ 55 years). In addition, 160 
stratified meta-analyses were also conducted on dose of zinc (<35 mg/day and ≥ 35 mg/day) 161 
and trial duration (in weeks). It was not possible to perform a stratified meta-analysis for 162 
gender, because most studies included both men and women and data were not available at 163 
the individual level.  164 
 The transformations used to derive coherent single-study estimates from the available 165 
summary statistics per study have been described elsewhere (16) . In short, an intake-status 166 
regression coefficient ( ) for each individual study was estimated from the mean 167 
serum/plasma zinc concentrations, based on the assumption of a linear relation on the loge-168 
loge-scale (natural logarithm of intake versus natural logarithm of status). Algebraically 169 
deriving an estimate from each study of the regression coefficient ( ) and its standard error 170 
(SE( )) enabled a comparison of  the results from studies with heterogeneously reported 171 
associations and effects. The overall pooled  and SE( ) was calculated using random effects 172 
meta-analysis, which estimates the between-study variance using the method of DerSimonian 173 
and Laird (17). This was then used to modify the weights used to calculate the summary 174 
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estimate. Residual heterogeneity between studies was evaluated using the I2 statistic. To 175 
evaluate potential sources of heterogeneity, the variables study duration, age, gender and zinc 176 
dose were added simultaneously to a meta-regression model as continuous variables. The 177 
statistical transformations to obtain ’s and SE( )’s were performed using GenStat version 178 
13-SP2 (VSN International Ltd. Hemel Hemptead, UK) and the meta-analysis was performed 179 
using STATA version 11.0, with statistical significance defined as P<0.05. 180 
 181 
Assessment of risk of bias in included studies 182 
In order to assess the quality of the included studies and the risk of bias, indicators of internal 183 
validity were collected during data extraction (Table 3). Based on the indicators two 184 
independent reviewers assessed the overall risk of bias and disagreements resolved by 185 
discussion. The criteria for judging these indicators were adapted from the Cochrane 186 
Handbook for Systematic Reviews (18). 187 
Results 188 
Twenty estimates of zinc intake and serum/plasma zinc status in 10 RCTs and four estimates 189 
in 3 observational studies were eligible for meta-analysis. All studies were published between 190 
1979 and 2010. Although plasma/serum, urine and hair zinc concentrations were included as 191 
markers of status in the systematic review protocol, only plasma/serum zinc concentration 192 
was reported universally and sufficiently frequently to be used in the meta-analysis. Most 193 
studies included, but did not differentiate between, males and females, but three studies 194 
included only females (19; 9; 20), two included only males (13; 8) and one provided both male and 195 
female data (14). Studies were conducted in Europe (n=7), North America (n=3), South Asia 196 
(n=1), East Asia (n=1) and Australasia (n=1) and ages of participants ranged from 18 to 106 197 
years. 198 
All but one RCTs used a parallel design. Boukaïba and colleagues employed a cross-199 
over RCT design (6). The RCTs included 1285 participants in total with sample sizes ranging 200 
from 5-201. The median duration of the trials was 25 weeks (range 2-52 weeks). In 9 studies 201 
zinc was supplemented alone at doses ranging from 15-135.3 mg/day and in 1 study zinc was 202 
provided within a multi-micronutrient supplement (12). Most studies (n=7) provided the zinc 203 
supplements in the form of zinc gluconate, but others used zinc sulphate (21), zinc acetate (7), 204 
or zinc carnosine (11). Habitual zinc intakes ranged from 5.4-10.8 mg/day (where data was 205 
provided). 206 
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The observational studies included 1184 participants in total with sample sizes 207 
ranging from 170-500. Zinc intake was measured using a combination of FFQ and 24 hour 208 
recall, or 24 hour recall alone and values ranged from 8.6-12.2 mg/day. The meta-analysis of 209 
available studies suggested that zinc supplementation was associated with increased 210 
serum/plasma zinc concentrations. The estimated effect for zinc supplementation on 211 
serum/plasma zinc concentrations from RCTs and observational studies was 0.08 (95% CI 212 
0.05, 0.11; p<0.0001; I2 84.5%) (Fig 2). When data sets were grouped according to study 213 
design, only the RCTs showed a significant effect size (0.09 95% CI 0.07, 0.120; p<0.0001; 214 
I2 79.1%).   215 
Since a base-e logarithmic transformation was applied to the zinc intake and 216 
serum/plasma zinc concentration before calculation of the study-specific ’s, the overall  217 
represents the difference in the logetransformed predicted value of serum/plasma zinc status 218 
for each one-unit difference in the logetransformed value in zinc intake. Therefore, an overall 219 
 of 0.08 means that for every doubling in zinc intake, the difference in zinc serum or plasma 220 
concentration is  (20.08 = 1.06), which is 6%. This means that a person with a zinc intake of 221 
14 mg/day has a zinc serum/plasma concentration that is 6% higher than a person who has a 222 
zinc intake of 7 mg/day (Fig 3).   223 
As plasma/serum zinc concentrations have been reported to decline with age (15), a 224 
separate subgroup analysis compared zinc intake and status according to age in RCTs (< 55 225 
years and  ≥ 55 years). Two studies for which mean serum/plasma zinc values were given for 226 
adults whose ages spanned both age groups were excluded from this analysis (12; 11). A 227 
stronger effect size was found in adults aged under 55 years (0.14 95% CI 0.04, 0.24; 228 
p<0.005; I2 92.1%) compared to adults aged 55 years and over (0.09 95% CI 0.07, 0.11; 229 
p<0.0001; I2 32.8%), although care should be taken with interpreting this finding as the 230 
younger age group analysis is based on only three estimates in two studies. Stratifying the 231 
analysis for dose of zinc (<35 mg/day and ≥ 35 mg/day) revealed a stronger effect size for a 232 
zinc dose ≥ 35mg/d (0.14 95% CI 0.08, 0.21; p<0.0001; I2 85.2%) compared to <35mg/d 233 
(0.09 95% CI 0.07, 0.10; p<0.005; I2 27.6%). Similar effect sizes were demonstrated for 234 
study duration (0-12 weeks 0.13 CI 0.05, 0.20 I2 92.4% and > 12 weeks 0.10 CI 0.07, 0.12 I2 235 
75.8%). 236 
  To evaluate potential sources of heterogeneity, the variables duration, age, gender and 237 
dose were added simultaneously to a meta-regression model as continuous variables. The 238 
analysis revealed that only zinc dose was a statistically significant determinant of the overall 239 
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beta. The model explained 50% of between-study variance and the residual variation due to 240 
heterogeneity was reduced to 48.2%. 241 
 242 
Table 4 summarises the internal validity of the included studies, assessed as described 243 
in the methods section. The risk of bias was high in 5 out of the 10 papers (21; 6; 22; 23; 11) .  244 
Papers were given a high risk of bias rating due to insufficient information provided on 245 
sequence generation and/or allocation, drop-outs and funding bodies. 246 
 247 
Discussion 248 
The current study is unique in providing an estimate of the dose-response relationship of zinc 249 
intake and serum/plasma zinc concentrations in adults.  A meta-analysis of 20 estimates in 10 250 
RCTs and 4 estimates in 3 observational studies found that zinc supplementation produced a 251 
statistically significant increase in serum/plasma zinc concentrations and provided an 252 
estimate of the dose-response relationship between zinc intake and serum/plasma 253 
concentrations. An overall  of 0.08 means that for every doubling in zinc intake, the 254 
difference in zinc serum or plasma concentration is 6%. In other words, an adult with a zinc 255 
intake of 14 mg/day has a zinc serum/plasma concentration that is 6% higher than a person 256 
who has a zinc intake of 7 mg/day. This association was slightly stronger when considering 257 
only the RCTs, as no observational studies found a significant association between zinc 258 
intake and plasma zinc concentrations. The intake-status regression coefficient for the 259 
observational studies is likely to be attenuated by random and intake-related errors in 260 
assessing dietary zinc intake (24), whereas in RCTs zinc intake can be considered as fixed at 261 
each level of dosage and random errors arise only through assessment of biomarkers.  262 
The studies included in this meta-analysis were different in a number of aspects, such 263 
as using various designs, follow-up times, zinc doses, and populations. Therefore, it is no 264 
surprise that, when combining these studies in a meta-analysis, a large heterogeneity is 265 
observed between the studies (I2 = 84.5% p=0.0001). This between-study heterogeneity may 266 
be caused by methodological factors, such as differences in study population characteristics 267 
(age, socio-economic status) or differences in doses of provided zinc (amount, one or more 268 
doses per day, study duration). When considering some key variables (study duration, zinc 269 
dose, age, and gender) in a meta-regression model, only dose explained some between-study 270 
heterogeneity. An individual participant data meta-analysis may have provided a more 271 
conclusive explanation of the between-study heterogeneity in this meta-analysis. However, 272 
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this type of analysis would involve the input of raw individual participant data provided by 273 
the original study investigators for re-analysis and combination in a pooled analysis and as 274 
such would be a major undertaking in terms of time, costs, and collaboration. Moreover, an 275 
inability to include individual participant data from all relevant studies could introduce 276 
selection bias. The meta-analytic approach used in this paper is not an attempt to accurately 277 
describe the biological relation between actual zinc intake and zinc concentrations in blood 278 
under strict experimental conditions and on an individual level, but rather to simulate a dose-279 
response relationship between zinc intake and status that is useful for surveillance studies 280 
with a public health point of view and, as such, deliberately incorporates the differences 281 
between dietary assessment methods,  laboratory assessment methods and participant 282 
characteristics to ensure a broad external validity. Thus, the heterogeneity reflects the lack of 283 
standardization of methods and the true heterogeneity between study populations and 284 
necessarily enters as uncertainty into the application of such data for public health purposes 285 
(25). 286 
To conduct this meta-analysis some assumptions related to the availability of the 287 
required data or related to statistical issues had to be made. First, when two or more 288 
intervention groups were compared to the same control group (5 RCTs), independence of 289 
estimates was assumed. As a consequence bias may have been introduced, by either 290 
increasing the estimates of the intervention effect (if the control group values were in fact 291 
lower), or decreasing the estimates of the intervention effect (if the control group values were 292 
higher). Second, the meta-analysis required transformations of the intake and biomarker data 293 
to a common scale, as the studies included in this meta-analyses had different ways of 294 
reporting the relation between zinc and serum/plasma zinc concentration . The different ways 295 
of reporting by transformation of both the intake and biomarker data were standardized to 296 
double loge-scale, which allowed the derivation of a standardized estimate from each study of 297 
the regression coefficient and its standard error as a basis for comparing these 298 
heterogeneously reported results. A linear relationship on the double loge-scale was also 299 
assumed. This transformation allowed the pooling of beta values and enable these to be 300 
reported as a dose-response relationship between zinc intake and serum/plasma zinc 301 
concentrations (16).  302 
The meta-analyses were conducted within the context of the EURRECA project as a 303 
means to provide additional evidence for underpinning reference values for zinc intake of 304 
populations. This dose-response relationship methodology may be used as either qualitative 305 
or quantitative evidence to substantiate the daily zinc intake dose necessary to achieve normal 306 
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or optimal levels of biomarkers for zinc status.  The dose-response relationship between zinc 307 
intake and plasma zinc concentration is of course subject to the debate around the usefulness 308 
of plasma/serum zinc concentration as a biomarker of zinc status, and the it’s predictive value 309 
for relevant functional health outcomes, such as markers of immune function. 310 
The relationship observed between serum/plasma zinc concentration and zinc intake 311 
may have been weakened by the limitation of this particular biomarker for zinc status. It is 312 
well established that plasma zinc concentration can fall in response to factors unrelated to 313 
zinc status or dietary zinc intake, such as infection, inflammation, exercise, stress or trauma 314 
(26). Conversely, tissue catabolism during starvation can release zinc into the circulation, 315 
causing a transient increase in circulating zinc levels. Six studies used non-fasted blood 316 
samples in their analyses (5; 7; 27; 20; 11; 14). As postprandial plasma zinc concentrations have 317 
been reported to fall up to 19% (28), the inclusion of these studies  may have weakened the 318 
observed relationship between zinc intake and status. Whilst all studies included in the 319 
analysis were undertaken in individuals without chronic disease or severe protein-energy 320 
malnutrition, other factors such as stress, infection and inflammation may also have gone 321 
unreported.  In addition, serum zinc concentration has been reported to decrease with age (15).   322 
Clearly such confounders have a strong influence on the interpretation of plasma zinc 323 
concentrations. However, as more sensitive indices of zinc status have yet to be identified, 324 
plasma serum zinc remains by far the most commonly used biomarker of zinc status (4).  325 
In conclusion, the current study presents the application of a novel technique to 326 
analyse data from 10 RCT’s and 3 observational studies reporting the relationship between 327 
zinc intake and serum/plasma zinc concentration.  This meta-analysis has provided an 328 
estimate of the dose-response relationship between zinc intake and serum/plasma zinc 329 
concentration in adults and elderly populations. Based on 24 estimates among 2469 330 
participants, the results indicate that a doubling of zinc intake increases plasma/serum levels 331 
by 6%. There is a high level of heterogeneity in the data obtained from the studies included in 332 
this meta-analysis.  Analysis of the factors that may contribute to this, namely study duration, 333 
zinc dose, age, and gender,   indicated that zinc dose was able to explain 50% of this 334 
heterogeneity.  This novel method of analyzing intake/biomarker relationships may be useful 335 
for the setting of future dietary zinc recommendations. 336 
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Figure Legends 454 
Figure 1 Study selection process for systematic review  455 
Figure 2 Random effects meta-analyses of RCTs and observational studies evaluating the 456 
pooled effect of dietary zinc on serum/plasma zinc in adults.  Beta values (♦) represent the 457 
regression coefficients for the linear association between loge transformed zinc intake and 458 
loge transformed serum/plasma zinc status. 459 
Figure 3 Serum/plasma zinc concentration (µmol/L) as a function of dietary zinc intake 460 
(mg/day), estimated by random-effects meta-analyses of RCTs of adults 461 
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Table 1. Ovid MEDLINE search strategy. 
No.  Search term Results 
1 randomized controlled trial.pt. 280821  
2 controlled clinical trial.pt. 79998  
3 randomized.ab. 196604  
4 placebo.ab. 117891  
5 clinical trials as topic.sh. 146242  
6 randomly.ab. 145491  
7 trial.ab. 203467  
8 randomised.ab. 38423  
9 6 or 3 or 7 or 2 or 8 or 1 or 4 or 5 734511  
10 (animals not (human and animals)).sh. 4482479  
11 9 not 10 642665  
12 (cohort* or ''case control*'' or cross-sectional* or ''cross sectional'' or case-control* or prospective or ''systematic review*'').mp. 768885  
13 exp meta-analysis/ or expmulticenter study/ or follow-up studies/ or prospective studies/ or intervention studies/ or 
epidemiologic studies/ or case-control studies/ or exp cohort studies/ or longitudinal studies/ or cross-sectional studies/ 
1013635  
14 13 or 12 1203767  
15 14 not 10 1154385  
16 11 or 15 1599094  
17 ((zinc or zn or zinc sulphate or zinc gluconate or zinc acetate or methionine or zinc isotope*) adj3 (intake* or diet* or 
supplement* or deplet* or status or serum or plasma or leukocyte or concentration* or expos* or fortif* or urine or hair)).ti,ab. 
16681  
18 Nutritional Support/ or Dietary Supplements/ or nutritional requirements/ or Breast feeding/ or exp infant food/ or bottle 
feeding/ or infant formula/ 
63098  
19 exp Nutritional Status/ or exp Deficiency Diseases/ or supplementation/ or diet supplementation/ or dietary intake/ or exp diet 
restriction/ or exp mineral intake/ or Diet/ or Food, Fortified/ or nutrition assessment/ or Nutritive Value/ 
176014  
20 (intake* or diet* or supplement* or deplet* or status or serum or plasma or leukocyte or concentration* or expos* or fortif* or 
urine or hair).ti,ab. 
3166092  
21 18 or 19 or 20 3263114  
22 zinc/ 41027  
23 22 and 21 20745  
24 23 or 17 26943  
25 24 and 16 2410  
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Table 2: Randomised controlled trials (n=10) reporting the effect of dietary zinc intake on serum/plasma zinc status in adults. 
First author, 
year, country 
Gender, age  Treatment groups  
 
Micronutrient 
type 
Duration Status marker 
reported 
[analytic 
method] 
Abdulla, 1979 
Sweden (5) 
Mean age 25 y.  
SD, age range, gender not 
reported 
 
Study 1 
Placebo (n=5) 
135.3mg/d Zn (n=7) 
Study 2 
Placebo (n=8) 
45mg/d Zn (n=7) 
 
Zinc sulphate 12 wk Plasma Zn 
[AAS] 
Bodgen, 1988 
USA (6) 
Males and females aged 
60- 89 y  
 
Placebo (n=36) 
15 mg/d Zn (n=36) 
100 mg/d Zn (n=31) 
 
Zinc acetate 3 mo Plasma Zn 
[AAS] 
Boukaïba, 
1993 
Males and females aged 
73-106 y  
BMI ≤ 21 
Placebo (n=21) 
Zinc gluconate 8 wk Serum Zn 
[AAS] 
19 
 
France (4) 
 
 20mg/d Zn (n=21) 
BMI ≥ 24 
Placebo (n=23) 
20mg/d Zn (n=23) 
 
Preziosi, 1998 
France (12) 
Males and females aged 
35-60 y 
 
Placebo (n=200) 
Multi-micronutrient supplement (20mg/d Zn) (n=201) 
 
Zinc gluconate 3 & 6 mo Serum Zn 
[AAS] 
Sullivan, 1998 
USA (11) 
Males aged 19- 35 y 
 
Placebo (n=13) 
50mg/d Zn (n=13) 
 
Zinc gluconate 15 d Plasma Zn 
[AAS] 
Feillet-
Coudray, 2005 
France (8) 
Males aged 58-68 y  
 
Placebo (n=16) 
15 mg/d Zn (n=16) 
30 mg/d Zn (n=16) 
 
Zinc gluconate 6 mo  Plasma Zn 
[ICP-MS] 
Feillet-
Coudray, 2006 
France (7) 
Females aged 55-70 y  
 
 
Placebo (n=16) 
15 mg/d Zn (n=16) 
30 mg/d Zn (n=15) 
Zinc gluconate 6 mo Serum Zn 
[ICP-MS] 
20 
 
 
Hininger-
Favier, 2007 
France, UK, 
Italy (9) 
Males and females aged 
55-85 y 
 
Age 55-70y 
Placebo (n=63) 
15mg/d Zn (n=60) 
30mg/d Zn (n=65) 
Age >70 y 
Placebo (n=67) 
15 mg/d Zn (n=66) 
30 mg/d Zn (n=66) 
 
Zinc gluconate 
 
 
6 mo Serum Zn 
[AAS] 
Prasad, 2007 
USA (21) 
Males and females aged 
55-87 y 
 
Placebo (n=25) 
45 mg/d Zn (n=24) 
 
Zinc gluconate 12 mo Plasma Zn 
[AAS] 
Sakagami, 
2009 
Japan (10) 
Males and females aged 
21-77 y 
 
 
Placebo (n=28) 
17 mg/d Zn (n=27) 
34 mg/d Zn (n=26) 
68 mg/d Zn (n=28) 
 
Zinc carnosine   12 wk Serum Zn 
[AAS] 
21 
 
 
 
AAS atomic absorption spectroscopy; ICP-MS inductively coupled plasma mass spectrometry 
 
 
 
Table 3: Observational studies (n=3) reporting the association between dietary zinc intake and serum/plasma zinc status in adults. 
 
First author, year,  
country 
N 
 
Mean (SD) 
zinc intake 
(mg/day) 
Mean (SD) 
plasma/serum 
zinc (µmol/L) 
Zinc intake 
(source) 
Zinc intake 
(assessment) 
Zinc status 
biomarker 
[analytical method] 
Gibson 2001 (New Zealand) 
(17) 
330 females aged 
18-40 y 
 
10.44 (3.51) 12.00 (1.36) Diet FFQ & 24 hr 
recall  
Serum zinc [AAS] 
Chandyo, 2009 (Nepal) (16) 
 
500 females aged 
13-35 y 
8.6 (3.3) 8.5 (2.4) Diet FFQ & 24 hr 
recall (2 days) 
Plasma zinc [ICP-
AES] 
Sánchez 2009 (Spain) (13) 170 males aged 12.24 (7.16) 17.48 (6.68) Diet 24 hr recall (2 Plasma zinc [AAS] 
22 
 
25-60 y 
184 females aged 
25-60 y 
 
9.07 (4.40) 
 
 
16.32 (6.21) 
days) 
 
AAS atomic absorption spectroscopy; ICP-MS inductively coupled plasma mass spectrometry 
23 
 
Table 4 Assessment of validity of included RCTs reporting zinc intake and serum/plasma zinc in adults  
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Abdulla 
1979 no no unclear no unclear unclear nr No yes no High  
Bodgen 
1988 yes yes yes yes nr yes yes 
 
no yes yes Low  
Boukaiba 
1993 unclear yes yes unclear yes  nr yes nr yes yes High 
Preziosi 
1998 yes yes yes unclear yes yes nr yes          yes yes High  
Sullivan 
1998 unclear unclear yes yes yes nr nr no yes yes High 
Feillet-
Coudray 
2005 
unclear yes yes yes yes yes unclear yes yes yes  Low  
Feillet-
Coudray 
unclear yes yes yes yes yes yes yes yes yes Low  
24 
 
 
nr: not reported 
 
 
 
 
2006 
Hininger-
Favier 
2007 
unclear yes unclear  yes yes yes yes yes yes yes  Low 
Prasad 
2007 yes yes yes yes yes yes nr yes yes yes Low  
Sakagami
2009 unclear yes yes unclear nr yes nr yes yes unclear High 
Figure 1 Study selection process for systematic review  
 
7154 abstracts identified by 
database search  
5 abstracts added by hand 
from review articles 
2440 Duplicates removed 
4719 Abstracts screened 
2557 excluded 
931 infant, child, 
pregnant, lactating 
populations 
1231 adult 
populations
1147 Excluded 
Not relevant design, not healthy 
populations, not relevant status 
measure, not relevant intake measure, 
not relevant study population, no 
baseline measures for outcome of 
interest, no adequate control group, 
not relevant intervention, not reported 
amount of zinc provided, no values 
provided for outcome of interest, 
companion paper, only abstract 
available 
 
84 Intake-status-health 
final library  
35 Status-Health relationships
(some papers reported both S-H & 
I-H relationships) 
Intake-Status  
relationships: 
30 RCTs 
7 Observational  
15 Intake -Health relationships
(some papers reported both S-H & I-
H relationships) 
Excluded from the meta-analysis: 
20 RCTs & 4 Observational: 
Participants not healthy, 
insufficient data reported, 
duplicate data, dose unclear, 
duration unclear Included in the meta-
analysis 
10 RCTs 
3 Observational 
Figure 2 Random effects meta-analyses of RCTs and observational studies evaluating the 
pooled effect of dietary zinc on serum/plasma zinc in adults.  Beta values (♦) represent the 
regression coefficients for the linear association between loge transformed zinc intake and 
loge transformed serum/plasma zinc status. 
 
 
1: RCTs; 2: Observational studies 
 
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 84.5%, p = 0.000)
Sakagami, 2009 (17 mg/d)
Subtotal  (I-squared = 54.1%, p = 0.088)
Prasad, 2007 (15 mg/d)
Boukaiba, 1993 (20 mg/d) BMI ? 24
Feillet-Coudray, 2006 (15 mg/d) Females
Sakagami, 2009 (68 mg/d)
Abdulla, 1979 (45 mg/d)
Sanchez, 2009
Hininger-Favier, 2007 (30 mg/d) Age 55-70y
Gibson, 2001
Sanchez, 2009
Feillet-Coudray, 2005 (30 mg/d) Males
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Preziosi, 1998 (20 mg/d)
Feillet-Coudray, 2005 (15 mg/d) Males
2
Chandyo, 2009
Hininger-Favier, 2007 (15 mg/d) Age >70 y
Feillet-Coudray, 2006 (30 mg/d) Females
Bodgen, 1988 (15 mg/d)
1
study
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 Figure 3 Serum/plasma zinc concentration (µmol/L) as a function of dietary zinc intake 
(mg/day), estimated by random-effects meta-analyses of RCTs of adults 
 
 
 
 
 
